.avif)
Cytokinetics Email Format
Biotechnology Research
・
501-1,000 employees
・
South San Francisco, CA, USA
Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing first-in-class muscle activators and inhibitors for diseases where muscle performance is compromised.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@cytokinetics.com
Company Overview
Industry
Biotechnology Research
Founded
1998
Headquarters
South San Francisco, CA, USA
Revenue
$10M-$25M
FUNDING Stage
Public
Website
Key Executives
Robert I. Blum (President and Chief Executive Officer), Sung Lee (Executive Vice President and Chief Financial Officer), Scott R. Jordan (SVP, Global Marketing & Commercial Strategy)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Cytokinetics?
Cytokinetics uses the firstinitiallast format, so Jane Smith would be jsmith@cytokinetics.com.
What disease does Cytokinetics' approved drug MYQORZO treat?
MYQORZO (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe, and China for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics launched it commercially in the U.S. in late January 2026.
How large is Cytokinetics as a company?
Cytokinetics employs approximately 761 people and is headquartered in South San Francisco, California. Tools like Clay can help you find and verify specific contacts at the company for outreach.
Who leads Cytokinetics as its CEO?
Robert I. Blum serves as President and Chief Executive Officer of Cytokinetics. The company's executive team also includes Sung Lee as Chief Financial Officer and Scott R. Jordan as SVP of Global Marketing and Commercial Strategy.
Beyond MYQORZO, what other compounds does Cytokinetics have in its pipeline?
Cytokinetics is advancing omecamtiv mecarbil in the Phase 3 COMET-HF trial for heart failure with severely reduced ejection fraction, and ulacamten in the Phase 2 AMBER-HFpEF trial, alongside early-stage skeletal muscle programs.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating